The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Polyatskin I.L.

N.N.Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russia

Artem'eva A.S.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Krivolapov Yu.A.

Pathoanatomical Department of Clinical Molecular Morphology, E.E. Eichwald Clinic, I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg, Russia

Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition):lymphoid tumors (in Russian only)

Authors:

Polyatskin I.L., Artem'eva A.S., Krivolapov Yu.A.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2019;81(3): 59‑65

DOI: 10.17116/patol20198103159

Views: 5196

Downloaded: 588

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Polyatskin IL, Artem'eva AS, Krivolapov YuA. Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition):lymphoid tumors (in Russian only). Russian Journal of Archive of Pathology. 2019;81(3):59‑65. (In Russ.)
https://doi.org/10.17116/patol20198103159

Подписка 2025 (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Close metadata

The paper is devoted to changes in the 4th edition of the WHO classification of lymphoid tumors in the 2017 revision, to the principles of the structure and features of the classification. It discusses changes in the identification of new clinical and morphological categories and in the abolition of some previously existing ones. New information about lymphoid tumors, their immunophenotypic and molecular characteristics of classification importance are briefly outlined. The absolute need for molecular genetic studies for the diagnosis of certain lymphoproliferative diseases is underlined. The characteristics of lymphoid pretumor states are given.

Keywords:

classification of lymphoid tumors
lymphoblastic leukemia
B-cell lymphomas
T-cell lymphomas

Authors:

Polyatskin I.L.

N.N.Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russia

Artem'eva A.S.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Krivolapov Yu.A.

Pathoanatomical Department of Clinical Molecular Morphology, E.E. Eichwald Clinic, I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg, Russia

List of references:

  1. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, Van Zutven LJ, Beverloo HB, Van der Spek PJ, Escherich G, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125-134. https://doi.org/10.1016/s1470-2045(08)70339-5
  2. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-1015.
  3. Harrison CJ, Moorman AV, Schwab C, Carroll AJ, Raetz EA, Devidas M, Strehl S, Nebral K, Harbott J, Teigler-Schlegel A, et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia. 2014;28(5):1015-1021. https://doi.org/10.1038/leu.2013.317
  4. Heerema NA, Carroll AJ, Devidas M, Loh ML, Borowitz MJ, Gastier-Foster JM, Larsen EC, Mattano LAJr, Maloney KW, Willman CL, et al. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children’s oncology group studies: a report from the children’s oncology group. J Clin Oncol. 2013;31(27):3397-3402. https://doi.org/10.1200/jco.2013.49.1308
  5. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147-156. https://doi.org/10.1016/s1470-2045(08)70314-0
  6. Sedick Q, Alotaibi S, Alshieban S, Naheet KB, Elyamany G. Natural killer cell lymphoblastic leukaemia/lymphoma: case report and review of the recent literature. Case Rep Oncol. 2017;10(2):588-595. https://doi.org/10.1159/000477843
  7. Swerdlow SH, Campo E, Harris NL, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC; 2017.
  8. Rawstron AC, Shanafelt T, Lanasa MC, Landgren O, Hanson C, Orfao A, Hillmen P, Ghia P. Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry B Clin Cytom. 2010; 78(Suppl.1):S19-S23. https://doi.org/10.1002/cyto.b.20533
  9. Xochelli A, Kalpadakis C, Gardiner A, Baliakas P, Vassilakopoulos TP, Mould S, Davis Z, Stalika E, Kanellis G, Angelopoulou MK, et al. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity? Blood. 2014;123(8):1199-1206. https://doi.org/10.1182/blood-2013-07-515155
  10. Bruscaggin A, Monti S, Arcaini L, Ramponi A, Rattotti S, Lucioni M, Paulli M, Gaidano G, Rossi D. Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features. Br J Haematol. 2014;167(5):718-720. https://doi.org/10.1111/bjh.13052
  11. Gibson SE, Leeman-Neill RJ, Jain S, Piao W, Cieply KM, Swerdlow SH. Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene. Br J Haematol. 2016;175(1):173-175. https://doi.org/10.1111/bjh.13844
  12. Giné E, Martinez A, Villamor N, López-Guillermo A, Camos M, Martinez D, Esteve J, Calvo X, Muntañola A, Abrisqueta P, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia («accelerated» chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010;95(9):1526-1533. https://doi.org/10.3324/haematol.2009.022277
  13. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714-726. https://doi.org/10.1016/j.cell.2013.01.019
  14. Villamor N, Conde L, Martínez-Trillos A, Cazorla M, Navarro A, Beà S, López C, Colomer D, Pinyol M, Aymerich M, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013;27(5):1100-1106. https://doi.org/10.1038/leu.2012.357
  15. Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, Jares P, Navarro A, Martín-García D, Beà S, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016;127(17):2122-2130. https://doi.org/10.1182/blood-2015-07-659144
  16. The International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a metaanalysis of individual patient data. Lancet Oncol. 2016;17(6):779-790. https://doi.org/10.1016/s1470-2045(16)30029-8
  17. Falini B, Martelli MP, Tiacci E. BRAF V600E mutation in hairy cell leukemia: from bench to bedside. Blood. 2016;128(15):1918-27. https://doi.org/10.1182/blood-2016-07-418434
  18. Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46(1):8-10. https://doi.org/10.1038/ng.2828
  19. Xu L, Hunter ZR, Yang G, Cao Y, Liu X, Manning R, Tripsas C, Chen J, Patterson CJ, Kluk M, et al. Detection of MYD88 L265P in peripheral blood of patients with Waldenstrom’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Leukemia. 2014;28(8):1698-1704. https://doi.org/10.1038/leu.2014.65
  20. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood. 2011;117(21):5573-5581. https://doi.org/10.1182/blood-2011-01-270140
  21. Taddesse-Heath L, Pittaluga S, Sorbara L, Bussey M, Raffeld M, Jaffe ES. Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol. 2003;27(4):522-531. https://doi.org/10.1097/00000478-200304000-00014
  22. Tellier J, Menard C, Roulland S, Martin N, Monvoisin C, Chasson L, Nadel B, Gaulard P, Schiff C, Tarte K. Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis? Blood. 2014;123(22):3462-3465. https://doi.org/10.1182/blood-2013-12-545954
  23. Jegalian AG, Eberle FC, Pack SD, Mirvis M, Raffeld M, Pittaluga S, Jaffe ES. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood. 2011;118(11):2976-2984. https://doi.org/10.1182/blood-2011-05-355255
  24. Schmatz A, Streubel B, Kretschmer-Chott E, Püspök A, Jäger U, Mannhalter C, Tiemann M, Ott G, Fischbach W, Herzog P. Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol. 2011;29(11):1445-1451. https://doi.org/10.1200/jco.2010.32.9193
  25. Louissaint AJr, Schafernak KT, Geyer JT, Kovach AE, Ghandi M, Gratzinger D, Roth CG, Paxton CN, Kim S, Namgyal C, et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood. 2016;128(8):1093-1100. https://doi.org/10.1182/blood-2015-12-682591
  26. Salaverria I, Martin-Guerrero I, Burkhardt B, Kreuz M, Zenz T, Oschlies I, Arnold N, Baudis M, Bens S, García-Orad A, et al. High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas. Genes Chromosomes Cancer. 2013;52(2):150-155. https://doi.org/10.1002/gcc.22014
  27. Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, Catovsky D, Thomas PW, Avet-Loiseau H, Oscier D. A subset of t(11;14) lymphoma with mantle cell features displays mutated lgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975-4981. https://doi.org/10.1182/blood-2002-06-1864
  28. Del Giudice I, Messina M, Chiaretti S, Santangelo S, Tavolaro S, De Propris MS, Nanni M, Pescarmona E, Mancini F, Pulsoni A, et al. Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes. Br J Haematol. 2012;156(5):601-611. https://doi.org/10.1111/j.1365-2141.2011.08962.x
  29. Carvajal-Cuenca A, Sua LF, Silva NM, Pittaluga S, Royo C, Song JY, Sargent RL, Espinet B, Climent F, Jacobs SA, et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica. 2012;97(2):270-278. https://doi.org/10.3324/haematol.2011.052621
  30. Katzenstein AL, Doxtader E, Narendra S. Lymphomatoid granulomatosis: insights gained over 4 decades. Am J Surg Pathol. 2010; 34(12):e35-e48. https://doi.org/10.1097/pas.0b013e3181fd8781
  31. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282. https://doi.org/10.1182/blood-2003-05-1545
  32. Clark Schneider KM, Banks PM, Collie AM, Lanigan CP, Manilich E, Durkin LM, Hill BT, Hsi ED. Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57(7):1640-1648. https://doi.org/10.3109/10428194.2015.1101099
  33. Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, et al. Age cutoff for Epstein—Barr virus-positive diffuse large B-cell lymphoma — is it necessary? Oncotarget. 2015;6(16):13933-13945. https://doi.org/10.18632/oncotarget.4324
  34. Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer — a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010;34(3):405-417. https://doi.org/10.1097/pas.0b013e3181cf8622
  35. Papoudou-Bai A, Hatzimichael E, Kyriazopoulou L, Briasoulis E, Kanavaros P. Rare variants in the spectrum of human herpesvirus 8/Epstein—Barr virus-copositive lymphoproliferations. Hum Pathol. 2015;46(10):1566-1571. https://doi.org/10.1016/j.humpath.2015.06.020
  36. Gonzalez-Farre B, Martinez D, Lopez-Guerra M, Xipell M, Monclus E, Rovira J, Garcia F, Lopez-Guillermo A, Colomo L, Campo E, Martinez A. HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. Mod Pathol. 2017;30(5):745-760. https://doi.org/10.1038/modpathol.2016.233
  37. Salaverria I, Martin-Guerrero I, Wagener R, Kreuz M, Kohler CW, Richter J, Pienkowska-Grela B, Adam P, Burkhardt B, Claviez A, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood. 2014;123(8):1187-1198. https://doi.org/10.1182/blood-2013-06-507996
  38. Yoshida M, Ichikawa A, Miyoshi H, Kimura Y, Arakawa F, Niino D, Ohshima K. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements. Pathol Int. 2015;65(10):519-527. https://doi.org/10.1111/pin.12335
  39. Ohshima K, Kimura H, Yoshino T, Kim CW, Ko YH, Lee SS, Peh SC, Chan JK; CAEBV Study Group. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int. 2008;58(4):209-217. https://doi.org/10.1111/j.1440-1827.2008.02213.x
  40. Deleeuw RJ, Zettl A, Klinker E, Haralambieva E, Trottier M, Chari R, Ge Y, Gascoyne RD, Chott A, Müller-Hermelink HK, Lam WL. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology. 2007;132(5):1902-1911. https://doi.org/10.1038/ncomms7025
  41. Küçük C, Jiang B, Hu X, Zhang W, Chan JK, Xiao W, Lack N, Alkan C, Williams JC, Avery KN, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from yo-Tor NK cells. Nat Commun. 2015;6:6025. https://doi.org/10.1053/j.gastro.2007.03.036
  42. Nicolae A, Xi L, Pham TH, Pham TA, Navarro W, Meeker HG, Pittaluga S, Jaffe ES, Raffeld M. Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas. Leukemia. 2016;30(11):2245-2247. https://doi.org/10.1038/leu.2016.178
  43. Perry AM, Warnke RA, Hu Q, Gaulard P, Copie-Bergman C, Alkan S, Wang HY, Cheng JX, Bacon CM, Delabie J, et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood. 2013;122(22):3599-606. https://doi.org/10.1182/blood-2013-07-512830
  44. Kluk J, Kai A, Koch D, Taibjee SM, O’Connor S, Persic M, Morris S, Whittaker S, Cerroni L, Kempf W, Petrella T, Robson A. Indolent CD8-positive lymphoid proliferation of acral sites: three further cases of a rare entity and an update on a unique patient. J Cutan Pathol. 2016;43(2):125-136. https://doi.org/10.1111/cup.12633
  45. James E, Sokhn JG, Gibson JF, Carlson K, Subtil A, Girardi M, Wilson LD, Foss F. CD4+ primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leuk Lymphoma. 2015;56(4):951-957. https://doi.org/10.3109/10428194.2014.938331
  46. Laurent C, Fazilleau N, Brousset P. A novel subset of T-helper cells: follicular T-helper cells and their markers. Haematologica. 2010;95(3):356-358. https://doi.org/10.3324/haematol.2009.019133
  47. King RL, Dao LN, McPhail ED, Jaffe ES, Said J, Swerdlow SH, Sattler CA, Ketterling RP, Sidhu JS, Hsi ED, et al. Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements. Am J Surg Pathol. 2016;40(1):36-43. https://doi.org/10.1097/pas.0000000000000500
  48. Pedersen MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, Bedroske PP, Luoma IM, Sattler CA, Boddicker RL, Bennani NN, Nørgaard P, et al. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood. 2017;130(4):554-557. https://doi.org/10.1002/hon.2439_157
  49. Xing X, Feldman AL. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. Adv Anat Pathol. 2015;22(1):29-49. https://doi.org/10.1097/pap.0000000000000047
  50. Thompson PA, Lade S, Webster H, Ryan G, Prince HM. Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity. Haematologica. 2010;95(11):1977-1979. https://doi.org/10.3324/haematol.2010.026237
  51. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016;34(2):160-168. https://doi.org/10.1200/jco.2015.63.3412
  52. Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27(10):1346-1356. https://doi.org/10.1097/00000478-200310000-00007

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.